论文部分内容阅读
目的：探讨氨磺必利对精神分裂症患者临床疗效及生活质量的影响。方法将125例精神分裂症患者随机分为两组，分别口服氨磺必利和利培酮治疗，观察24周。采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应，生活质量综合评定问卷评定生活质量。结果治疗4周末起两组阳性与阴性症状量表评分均较治疗前显著降低（P＜0．01），氨磺必利组治疗8周末起阴性症状因子分显著低于利培酮组（ P＜0．05或0．01），治疗24周末生活质量综合评定问卷躯体功能、心理功能、社会功能维度分均显著高于利培酮组（P＜0．01）。氨磺必利组月经紊乱、血脂异常、血糖异常等不良反应发生率显著低于利培酮组（P＜0．05）。结论氨磺必利与利培酮治疗精神分裂症疗效显著且相当，但氨磺必利在改善阴性症状及患者生活质量方面效果更好，安全性更高。“,”Objective To explore amisulpride’s influence on clinical efficacy and quality of life of schizo-phrenics .Methods A total of 125 chizophrenics were randomly divided into two groups ,they respectively took orally amisulpride and risperidone for 24 weeks .Efficacies were assessed with the Positive and Nega-tive Syndrome Scale (PANSS) ,adverse reactions with the Treatment Emergent Symptom Scale (TESS) and qualities of life with the Generic Quality of Life Inventory-74 (GQOLI-74) .Results Since the end of the 4th week the PANSS scores of both groups lowered more significantly compared with pretreatment (P<0 .01) ,since the end of the 8th week negative symptoms scores were significantly lower (P<0 .05 or 0 .01) and at the end of 24th week physical ,mental and social function score of the GQOLI-74 higher (P<0 .01)in amisulpride than risperidone group .The incidences of menstrual disorder ,abnormal blood lipid and glucose were significantly lower in amisulpride than risperidone group (P< 0 .05) .Conclusion both amisulpride and risperidone have an evident in schizophrenia ,but amisulpride improves negative symptoms and quality of life better and has higher safety .